1. Home
  2. |Insights
  3. |PODCAST: Trade and Jobs: What Trump Can and Can’t Do in the First 100 Days — C&M’s First 100 Days Series

PODCAST: Trade and Jobs: What Trump Can and Can’t Do in the First 100 Days — C&M’s First 100 Days Series

Client Alert | 1 min read | 12.20.16

Trade with Mexico and China were top issues for the Trump campaign, and recent developments suggest corporations may be in store for significant change under a Trump Administration. Could we be looking at an entirely different economic framework after January 20? How will manufacturers be impacted? Crowell & Moring International Trade Group partners Daniel Cannistra and John Brew discuss anxiety in the marketplace and how trade could change under President Trump.

Covered in this 23 minute podcast:

  • What are Trump’s promises on trade and can he fulfill them? What authority does the president have to alter trade agreements? What challenges might he face?
  • NAFTA and the possibility of tariffs on Mexican imports.
  • What can Trump do with respect to China?
  • What is the likelihood that the proposed border adjustment tax could go through?
  • What is a trade war, and what might cause it?
  • What agencies should large, multinational companies be looking to throughout the first 100 days to watch for trade updates?

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...